- August 26, 2025CD38: a Blockbuster sales target under fire by biosuperior and biosmilar antibody competitors – a pipeline review STUTTGART, Germany I…
- August 26, 2025TROP-2: a Blockbuster target with opportunities for new drug modalities – a pipeline review STUTTGART, Germany I August 26, 2025…
- August 26, 2025Nectin-4: a clinically and commercially validated target with limited competition – a pipeline review STUTTGART, Germany I August 26, 2025…
- August 20, 2025CCR8: an attractive immuno-oncology target for antibody therapy – a pipeline review STUTTGART, Germany I August 20, 2025 I La…
- August 19, 2025EpCAM: conditional activation technologies can make EpCAM a viable target – a pipeline review STUTTGART, Germany I August 19, 2025…
- August 19, 20255T4: a delicate target for sophisticated payload delivery – a pipeline review STUTTGART, Germany I August 19, 2025 I La…
- August 18, 2025B7-H4: a promising target for effector-enhanced drug modalities – a pipeline review STUTTGART, Germany I August 18, 2025 I La…
- August 18, 2025Mesothelin: an old solid tumor target for next generation drug modalities – a pipeline review STUTTGART, Germany I August 18,…
- August 15, 2025c-Met: a well-suited target for payload delivery by antibodies – a pipeline review STUTTGART, Germany I August 15, 2025 I…
- August 14, 2025STUTTGART, Germany I August 14, 2025 I Selecting the right target remains the most important decision to make in drug…
